{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:54:40Z","timestamp":1790708080817,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"30","license":[{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,7,28]]},"DOI":"10.1038\/onc.2015.464","type":"journal-article","created":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T11:03:44Z","timestamp":1449486224000},"page":"3955-3964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax"],"prefix":"10.1038","volume":"35","author":[{"given":"R","family":"Bajpai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Matulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H E","family":"Von Hollen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L H","family":"Boise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,7]]},"reference":[{"key":"BFonc2015464_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046\u20131060.","journal-title":"N Engl J Med"},{"key":"BFonc2015464_CR2","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J . Curing myeloma at last: defining criteria and providing the evidence. Blood 2014; 124: 3043\u20133051.","journal-title":"Blood"},{"key":"BFonc2015464_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","volume":"116","author":"NN Danial","year":"2004","unstructured":"Danial NN, Korsmeyer SJ . Cell death: critical control points. Cell 2004; 116: 205\u2013219.","journal-title":"Cell"},{"key":"BFonc2015464_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1097-2765(01)00320-3","volume":"8","author":"EH Cheng","year":"2001","unstructured":"Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705\u2013711.","journal-title":"Mol Cell"},{"issue":"Suppl 1","key":"BFonc2015464_CR5","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1038\/onc.2009.52","volume":"27","author":"T Ni Chonghaile","year":"2008","unstructured":"Ni Chonghaile T, Letai A . Mimicking the BH3 domain to kill cancer cells. Oncogene 2008; 27 (Suppl 1): S149\u2013S157.","journal-title":"Oncogene"},{"key":"BFonc2015464_CR6","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/sj.onc.1210679","volume":"27","author":"K Podar","year":"2008","unstructured":"Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT et al. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 2008; 27: 721\u2013731.","journal-title":"Oncogene"},{"key":"BFonc2015464_CR7","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0804821105","volume":"105","author":"JR Mills","year":"2008","unstructured":"Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 2008; 105: 10853\u201310858.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015464_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1535-7163.MCT-08-1159","volume":"8","author":"T Eguchi","year":"2009","unstructured":"Eguchi T, Itadani H, Shimomura T, Kawanishi N, Hirai H, Kotani H . Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines. Mol Cancer Ther 2009; 8: 1460\u20131472.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2015464_CR9","doi-asserted-by":"publisher","first-page":"19512","DOI":"10.1073\/pnas.0709443104","volume":"104","author":"M Nguyen","year":"2007","unstructured":"Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512\u201319517.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015464_CR10","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/onc.2009.448","volume":"29","author":"LA Pradelli","year":"2009","unstructured":"Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C et al. Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 2009; 29: 1641\u20131652.","journal-title":"Oncogene"},{"key":"BFonc2015464_CR11","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1182\/blood-2014-03-557298","volume":"124","author":"Z Liu","year":"2014","unstructured":"Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y et al. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 2014; 124: 2061\u20132071.","journal-title":"Blood"},{"key":"BFonc2015464_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/bjc.1997.487","volume":"76","author":"C Pepper","year":"1997","unstructured":"Pepper C, Hoy T, Bentley DP . Bcl-2\/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997; 76: 935\u2013938.","journal-title":"Br J Cancer"},{"key":"BFonc2015464_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.1206727","volume":"334","author":"T Ni Chonghaile","year":"2011","unstructured":"Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129\u20131133.","journal-title":"Science"},{"key":"BFonc2015464_CR14","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr., van Rhee F, Anaissie E et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114: 2068\u20132076.","journal-title":"Blood"},{"key":"BFonc2015464_CR15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1242\/jcs.21.3.609","volume":"21","author":"RS Roberts","year":"1976","unstructured":"Roberts RS, Hsu HW, Lin KD, Yang TJ . Amino acid metabolism of myeloma cells in culture. J Cell Sci 1976; 21: 609\u2013615.","journal-title":"J Cell Sci"},{"key":"BFonc2015464_CR16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","volume":"21","author":"S Dalva-Aydemir","year":"2015","unstructured":"Dalva-Aydemir S, Bajpai R, Martinez M, Adekola KU, Kandela I, Wei C et al. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin Cancer Res 2015; 21: 1161\u20131171.","journal-title":"Clin Cancer Res"},{"key":"BFonc2015464_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/msb.2012.20","volume":"8","author":"NA Graham","year":"2012","unstructured":"Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I et al. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol 2012; 8: 589.","journal-title":"Mol Syst Biol"},{"key":"BFonc2015464_CR18","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.1074\/jbc.M110.179101","volume":"286","author":"JL Coloff","year":"2011","unstructured":"Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, Nichols AN et al. Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem 2011; 286: 5921\u20135933.","journal-title":"J Biol Chem"},{"key":"BFonc2015464_CR19","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1128\/MCB.00153-07","volume":"27","author":"Y Zhao","year":"2007","unstructured":"Zhao Y, Altman BJ, Coloff JL, Herman CE, Jacobs SR, Wieman HL et al. Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol 2007; 27: 4328\u20134339.","journal-title":"Mol Cell Biol"},{"key":"BFonc2015464_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nature01825","volume":"424","author":"NN Danial","year":"2003","unstructured":"Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424: 952\u2013956.","journal-title":"Nature"},{"key":"BFonc2015464_CR21","doi-asserted-by":"publisher","first-page":"7315","DOI":"10.1128\/MCB.23.20.7315-7328.2003","volume":"23","author":"JC Rathmell","year":"2003","unstructured":"Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB . Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003; 23: 7315\u20137328.","journal-title":"Mol Cell Biol"},{"key":"BFonc2015464_CR22","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","volume":"99","author":"B Zhang","year":"2002","unstructured":"Zhang B, Gojo I, Fenton RG . Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885\u20131893.","journal-title":"Blood"},{"key":"BFonc2015464_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/blood.V100.1.194","volume":"100","author":"S Derenne","year":"2002","unstructured":"Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194\u2013199.","journal-title":"Blood"},{"key":"BFonc2015464_CR24","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","volume":"118","author":"AA Morales","year":"2011","unstructured":"Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 2011; 118: 1329\u20131339.","journal-title":"Blood"},{"key":"BFonc2015464_CR25","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1182\/blood-2011-09-377846","volume":"119","author":"SK McBrayer","year":"2012","unstructured":"McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST, Shanmugam M . Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood 2012; 119: 4686\u20134697.","journal-title":"Blood"},{"key":"BFonc2015464_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202\u2013208.","journal-title":"Nat Med"},{"key":"BFonc2015464_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2010.06.005","volume":"32","author":"FM Wensveen","year":"2010","unstructured":"Wensveen FM, van Gisbergen KP, Derks IA, Gerlach C, Schumacher TN, van Lier RA et al. Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones. Immunity 2010; 32: 754\u2013765.","journal-title":"Immunity"},{"key":"BFonc2015464_CR28","doi-asserted-by":"publisher","first-page":"e1052","DOI":"10.1038\/cddis.2014.6","volume":"5","author":"W Nakajima","year":"2014","unstructured":"Nakajima W, Hicks MA, Tanaka N, Krystal GW, Harada H . Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis 2014; 5: e1052.","journal-title":"Cell Death Dis"},{"key":"BFonc2015464_CR29","doi-asserted-by":"publisher","first-page":"36395","DOI":"10.1074\/jbc.M110.176321","volume":"285","author":"AK Vyas","year":"2010","unstructured":"Vyas AK, Koster JC, Tzekov A, Hruz PW . Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem 2010; 285: 36395\u201336400.","journal-title":"J Biol Chem"},{"key":"BFonc2015464_CR30","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/S0021-9258(17)30149-7","volume":"254","author":"RA Shapiro","year":"1979","unstructured":"Shapiro RA, Clark VM, Curthoys NP . Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site. J Biol Chem 1979; 254: 2835\u20132838.","journal-title":"J Biol Chem"},{"key":"BFonc2015464_CR31","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1021\/bi800097h","volume":"47","author":"G Brown","year":"2008","unstructured":"Brown G, Singer A, Proudfoot M, Skarina T, Kim Y, Chang C et al. Functional and structural characterization of four glutaminases from Escherichia coli and Bacillus subtilis. Biochemistry 2008; 47: 5724\u20135735.","journal-title":"Biochemistry"},{"key":"BFonc2015464_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183\u2013192.","journal-title":"Cancer Cell"},{"key":"BFonc2015464_CR33","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nrd2658","volume":"7","author":"G Lessene","year":"2008","unstructured":"Lessene G, Czabotar PE, Colman PM . BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989\u20131000.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2015464_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389\u2013399.","journal-title":"Cancer Cell"},{"key":"BFonc2015464_CR35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149\u20131159.","journal-title":"Lancet Oncol"},{"key":"BFonc2015464_CR36","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663\u20131674.","journal-title":"Blood"},{"key":"BFonc2015464_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","volume":"28","author":"C Touzeau","year":"2014","unstructured":"Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014; 28: 210\u2013212.","journal-title":"Leukemia"},{"key":"BFonc2015464_CR38","doi-asserted-by":"publisher","first-page":"e0116998","DOI":"10.1371\/journal.pone.0116998","volume":"10","author":"RR Olsen","year":"2015","unstructured":"Olsen RR, Mary-Sinclair MN, Yin Z, Freeman KW . Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism. PLoS One 2015; 10: e0116998.","journal-title":"PLoS One"},{"key":"BFonc2015464_CR39","doi-asserted-by":"publisher","first-page":"e1590","DOI":"10.1038\/cddis.2014.561","volume":"6","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6: e1590.","journal-title":"Cell Death Dis"},{"key":"BFonc2015464_CR40","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1101\/gad.215871.113","volume":"27","author":"RL Thomas","year":"2013","unstructured":"Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 2013; 27: 1365\u20131377.","journal-title":"Genes Dev"},{"key":"BFonc2015464_CR41","doi-asserted-by":"publisher","first-page":"5484","DOI":"10.1128\/MCB.00575-10","volume":"30","author":"LP Tuffy","year":"2010","unstructured":"Tuffy LP, Concannon CG, D'Orsi B, King MA, Woods I, Huber HJ et al. Characterization of Puma-dependent and Puma-independent neuronal cell death pathways following prolonged proteasomal inhibition. Mol Cell Biol 2010; 30: 5484\u20135501.","journal-title":"Mol Cell Biol"},{"key":"BFonc2015464_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1097-2765(00)80456-6","volume":"3","author":"H Puthalakath","year":"1999","unstructured":"Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A . The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287\u2013296.","journal-title":"Mol Cell"},{"key":"BFonc2015464_CR43","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1073\/pnas.0438011100","volume":"100","author":"K Lei","year":"2003","unstructured":"Lei K, Davis RJ . JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 2432\u20132437.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015464_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature12040","volume":"496","author":"J Son","year":"2013","unstructured":"Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496: 101\u2013105.","journal-title":"Nature"},{"key":"BFonc2015464_CR45","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V124.21.2067.2067","volume":"124","author":"MC Fabrizio Accardi","year":"2014","unstructured":"Fabrizio Accardi MC, Bolzoni M, Storti P, Todoerti K, Agnelli L, Ferrari M et al. Ammonium production and glutamine-addiction of myeloma cells: new attractive targets in multiple myeloma. Blood 2014; 124: 2067.","journal-title":"Blood"},{"key":"BFonc2015464_CR46","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 2014; 13: 890\u2013901.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2015464_CR47","doi-asserted-by":"publisher","first-page":"864058","DOI":"10.1155\/2014\/864058","volume":"2014","author":"SM Prideaux","year":"2014","unstructured":"Prideaux SM, Conway O'Brien E, Chevassut TJ . The genetic architecture of multiple myeloma. Adv Hematol 2014; 2014: 864058.","journal-title":"Adv Hematol"},{"key":"BFonc2015464_CR48","doi-asserted-by":"publisher","first-page":"26816","DOI":"10.1074\/jbc.M109.000646","volume":"284","author":"M Shanmugam","year":"2009","unstructured":"Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S et al. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem 2009; 284: 26816\u201326830.","journal-title":"J Biol Chem"},{"key":"BFonc2015464_CR49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","volume":"151","author":"TT Vo","year":"2012","unstructured":"Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012; 151: 344\u2013355.","journal-title":"Cell"},{"key":"BFonc2015464_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/1074-7613(95)90161-2","volume":"3","author":"LH Boise","year":"1995","unstructured":"Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995; 3: 87\u201398.","journal-title":"Immunity"},{"key":"BFonc2015464_CR51","doi-asserted-by":"publisher","first-page":"14441","DOI":"10.1074\/jbc.M114.628826","volume":"290","author":"RK Mishra","year":"2015","unstructured":"Mishra RK, Wei C, Hresko RC, Bajpai R, Heitmeier M, Matulis SM et al. In silico modeling-based identification of glucose transporter 4 (GLUT4)-selective inhibitors for cancer therapy. J Biol Chem 2015; 290: 14441\u201314453.","journal-title":"J Biol Chem"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2015464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2015464","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2015464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:05:08Z","timestamp":1647893108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2015464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,7]]},"references-count":51,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2016,7,28]]}},"alternative-id":["BFonc2015464"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.464","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,7]]},"assertion":[{"value":"17 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LHB is a consultant for Onyx Pharmaceuticals and Novartis; AKN is consultant for Onyx Pharmaceuticals and Spectrum pharmaceuticals; SL is a consultant for Millennium, Onyx Pharmaceuticals, Novartis, BMS, Janssen and Celgene. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}